How does 0P3C's PB Ratio compare to its peers?

0P3C is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (18.4x).

How does 0P3C's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

0P3C is good value based on its Price-To-Book Ratio (0.2x) compared to the European Pharmaceuticals industry average (2.3x).

What is 0P3C's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0P3C's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 0P3C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 0P3C's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Karolinska Development (LSE:0P3C) - Stock Price, News & Analysis

0P3C Stock Overview

A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. More details

0P3C fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue (SEK2M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (SEK285M)

Karolinska Development AB (publ) Competitors

Poolbeg Pharma

AIM:POLB

UK£36.3m

ECO Animal Health Group

AIM:EAH

UK£44.4m

Redx Pharma

AIM:REDX

UK£58.3m

Shield Therapeutics

AIM:STX

UK£22.7m

Price History & Performance

Summary of all time highs, changes and price drops for Karolinska Development
Historical stock prices
Current Share Price	SEK 1.22
52 Week High	SEK 1.82
52 Week Low	SEK 1.22
Beta	0.19
11 Month Change	0%
3 Month Change	n/a
1 Year Change	-32.93%
33 Year Change	-80.28%
5 Year Change	n/a
Change since IPO	-95.08%

Recent updates

Shareholder Returns

	0P3C	GB Pharmaceuticals	GB Market
7D	0%	4.2%	1.7%
1Y	-32.9%	3.0%	8.4%

Return vs Industry: 0P3C underperformed the UK Pharmaceuticals industry which returned 2.5% over the past year.

Return vs Market: 0P3C underperformed the UK Market which returned 8.8% over the past year.

Price Volatility

Is 0P3C's price volatile compared to industry and market?
0P3C volatility
0P3C Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0P3C's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0P3C's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2003	8	Viktor Drvota	www.karolinskadevelopment.com

Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.

Karolinska Development AB (publ) Fundamentals Summary

How do Karolinska Development's earnings and revenue compare to its market cap?
0P3C fundamental statistics
Market cap	SEK 285.48m
Earnings (TTM)	-SEK 28.53m
Revenue (TTM)	SEK 1.88m

152.0x

P/S Ratio

-10.0x

P/E Ratio

Is 0P3C overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0P3C income statement (TTM)
Revenue	SEK 1.88m
Cost of Revenue	SEK 0
Gross Profit	SEK 1.88m
Other Expenses	SEK 30.41m
Earnings	-SEK 28.53m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 14, 2025

Earnings per share (EPS)	-0.11
Gross Margin	100.00%
Net Profit Margin	-1,519.01%
Debt/Equity Ratio	0%

How did 0P3C perform over the long term?

See historical performance and comparison

0P3C Stock Overview

Risk Analysis

Karolinska Development AB (publ) Competitors

AIM:POLB

UK£36.3m

AIM:EAH

UK£44.4m

AIM:REDX

UK£58.3m

AIM:STX

UK£22.7m

Price History & Performance

Recent News & Updates

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Recent updates

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

First quarter 2023 earnings released

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Second quarter 2022 earnings released

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Investor sentiment deteriorated over the past week

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Less than half of directors are independent

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Shareholder Returns

Price Volatility